Cargando…
A Review on Currently Available Potential Therapeutic Options for COVID-19
A series of unexplained pneumonia cases currently were first reported in December 2019 in Wuhan, China. Official names have been announced for the virus responsible, previously known as “2019 novel coronavirus” and the diseases it causes are, severe acute respiratory syndrome coronavirus 2 (SARS-CoV...
Autor principal: | |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7387864/ https://www.ncbi.nlm.nih.gov/pubmed/32801840 http://dx.doi.org/10.2147/IJGM.S263666 |
_version_ | 1783564209158619136 |
---|---|
author | Ohadian Moghadam, Solmaz |
author_facet | Ohadian Moghadam, Solmaz |
author_sort | Ohadian Moghadam, Solmaz |
collection | PubMed |
description | A series of unexplained pneumonia cases currently were first reported in December 2019 in Wuhan, China. Official names have been announced for the virus responsible, previously known as “2019 novel coronavirus” and the diseases it causes are, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease (COVID-19), respectively. Despite great efforts worldwide to control SARS-CoV-2, the spread of the virus has reached a pandemic. Infection prevention and control of this virus is the primary concern of public health officials and professionals. Currently, several therapeutic options for COVID-19 are proposed and vaccine development has been initiated for prevention purposes. In this review, we will discuss the most recent evidence about the current potential treatment options including anti-inflammatory drugs, angiotensin-converting enzyme inhibitors/angiotensin receptor blockers, nucleoside analogs, protease inhibitors, monoclonal antibodies, and convalescent plasma therapy. Some other agents such as vitamin D and melatonin, which were recommended as potential adjuvant treatments for COVID-19 infection are also presented. Moreover, the potential use of convalescent plasma for treatment of COVID-19 infection was described. Furthermore, in the next part of the current review, various vaccination approaches against COVID-19 including whole virus vaccines, recombinant subunit vaccine, DNA vaccines, and mRNA vaccines are discussed. |
format | Online Article Text |
id | pubmed-7387864 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Dove |
record_format | MEDLINE/PubMed |
spelling | pubmed-73878642020-08-13 A Review on Currently Available Potential Therapeutic Options for COVID-19 Ohadian Moghadam, Solmaz Int J Gen Med Review A series of unexplained pneumonia cases currently were first reported in December 2019 in Wuhan, China. Official names have been announced for the virus responsible, previously known as “2019 novel coronavirus” and the diseases it causes are, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease (COVID-19), respectively. Despite great efforts worldwide to control SARS-CoV-2, the spread of the virus has reached a pandemic. Infection prevention and control of this virus is the primary concern of public health officials and professionals. Currently, several therapeutic options for COVID-19 are proposed and vaccine development has been initiated for prevention purposes. In this review, we will discuss the most recent evidence about the current potential treatment options including anti-inflammatory drugs, angiotensin-converting enzyme inhibitors/angiotensin receptor blockers, nucleoside analogs, protease inhibitors, monoclonal antibodies, and convalescent plasma therapy. Some other agents such as vitamin D and melatonin, which were recommended as potential adjuvant treatments for COVID-19 infection are also presented. Moreover, the potential use of convalescent plasma for treatment of COVID-19 infection was described. Furthermore, in the next part of the current review, various vaccination approaches against COVID-19 including whole virus vaccines, recombinant subunit vaccine, DNA vaccines, and mRNA vaccines are discussed. Dove 2020-07-24 /pmc/articles/PMC7387864/ /pubmed/32801840 http://dx.doi.org/10.2147/IJGM.S263666 Text en © 2020 Ohadian Moghadam. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
spellingShingle | Review Ohadian Moghadam, Solmaz A Review on Currently Available Potential Therapeutic Options for COVID-19 |
title | A Review on Currently Available Potential Therapeutic Options for COVID-19 |
title_full | A Review on Currently Available Potential Therapeutic Options for COVID-19 |
title_fullStr | A Review on Currently Available Potential Therapeutic Options for COVID-19 |
title_full_unstemmed | A Review on Currently Available Potential Therapeutic Options for COVID-19 |
title_short | A Review on Currently Available Potential Therapeutic Options for COVID-19 |
title_sort | review on currently available potential therapeutic options for covid-19 |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7387864/ https://www.ncbi.nlm.nih.gov/pubmed/32801840 http://dx.doi.org/10.2147/IJGM.S263666 |
work_keys_str_mv | AT ohadianmoghadamsolmaz areviewoncurrentlyavailablepotentialtherapeuticoptionsforcovid19 AT ohadianmoghadamsolmaz reviewoncurrentlyavailablepotentialtherapeuticoptionsforcovid19 |